Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Institut Curie currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct examiners and 3 distinct art units. This correspondence between actions, examiners, and art units suggests that each pending matter is being treated as a separate technical and administrative path. The involvement of 3 distinct art units indicates that the company's biotechnology research is being evaluated by diverse specialized groups within the office.
The busiest examiner, TRAN, ERIC, is currently managing 1 pending office action. This represents a portion of the total 3 pending office actions for the portfolio. The presence of multiple examiners for the active actions means that each examiner is currently handling exactly one matter for the portfolio. This structure requires the company to manage three separate administrative relationships within the patent office simultaneously.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, ERIC | 1 | 69.8% | +19.4% |
| KONOPKA, CATHERINE ANNE | 1 | 57.5% | +66.2% |
| REILLY, SOPHIA JANE | 1 | 60.0% | +49.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18284253 | PREPARATION METHOD OF QUINOLINE DERIVATIVE COMPOUNDS | REILLY, SOPHIA JANE | 20d |
| 18686403 | NITROGEN-CONTAINING DERIVATIVES OF NARASIN, SYNTHESIS AND USES THEREOF | TRAN, ERIC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18284253 | PREPARATION METHOD OF QUINOLINE DERIVATIVE COMPOUNDS | REILLY, SOPHIA JANE | 20d |
| 18686403 | NITROGEN-CONTAINING DERIVATIVES OF NARASIN, SYNTHESIS AND USES THEREOF | TRAN, ERIC | — |
| 18684020 | USE OF ETV3 OR ETV6 INHIBITORS FOR BLOCKING THE DIFFERENTIATION OF MONOCYTES INTO DENDRITIC CELLS | KONOPKA, CATHERINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1635 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18686403 | NITROGEN-CONTAINING DERIVATIVES OF NARASIN, SYNTHESIS AND USES THEREOF | TRAN, ERIC | 1629 | §103§112 | Final Rejection | — | Pending | Feb 23, 2024 |
| 18684020 | USE OF ETV3 OR ETV6 INHIBITORS FOR BLOCKING THE DIFFERENTIATION OF MONOCYTES INTO DENDRITIC CELLS | KONOPKA, CATHERINE ANNE | 1635 | §103 | Final Rejection | — | Pending | Feb 15, 2024 |
| 18284253 | PREPARATION METHOD OF QUINOLINE DERIVATIVE COMPOUNDS | REILLY, SOPHIA JANE | 1627 | §103§112 | Final Rejection | 20d | Pending | Sep 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInstitut Curie has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Eric Tran has the most, with 1 of Institut Curie's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
